Introduction
Genome-wide association studies (GWAS) provide a systematic assessment of the relationship between genetic variants and disease susceptibility. Recently, GWAS have become a method of choice for mapping genes involved in many complex diseases, including inflammatory bowel disease, 1, 2 multiple sclerosis, 3, 4 type 2 diabetes [5] [6] [7] [8] and type 1 diabetes (T1D). [9] [10] [11] [12] [13] [14] [15] [16] To date, GWAS have identified over 750 regions associated with more than 148 traits (GWAS catalog http://www.genome. gov/gwastudies). The number of genomic regions associated with each disease phenotype is quite large. Often, the regions showing association harbor many genes that potentially could contribute to the observed disease phenotypes. It has also become apparent that some of the associated regions are shared by multiple diseases with similar etiology. 17 The GWAS for T1D have suggested a large number of candidate associations with many regions overlapping between studies. 9, 10, 12, 14, 15, [18] [19] [20] As expected, several regions identified in these T1D GWAS are associated with known T1D-susceptibility genes, such as HLA (6p21.32), INS (11p15.5), PTPN22 (1p13.2), IFIH1 (2q24.2) and CTLA4 (2p33.2). However, hundreds of additional single-nucleotide polymorphisms (SNPs) are significantly associated (adjusted Po0.005) with T1D in multiple populations (http:// www.t1dgc.org). These SNPs represent 40 genomic regions, confirmed in multiple studies, and 70 regions with suggestive evidence (Po10 À4 ), 10 providing the diabetes scientific community with many new and exciting research opportunities, including identification of the specific disease genes, their roles in T1D pathogenesis, the specific genetic variants responsible for the disease, gene-environment interactions, genes and their encoded proteins that are useful as biomarkers for disease prediction, prognosis or as molecular targets for therapy, and the cellular functions associated with the genes/proteins and their signaling pathways.
Significant challenges remain in further exploring the information gained through GWAS, including the identification of disease genes and the elucidation of their potential function in T1D. One important task is to replicate these associations suggested by GWAS in other data sets. This study represents an attempt to replicate the GWAS associations using samples that have not been included in the previous GWAS. We genotyped 21 SNPs from the Medical College of Georgia (MCG), and 18 of the 21 SNPs provided evidence of association in the Georgia Caucasian population.
Results
We genotyped the MCG sample set for 21 SNPs that reached genome-wide significance level in one or multiple GWA studies. Overall, 18 SNPs remained significant at Po0.05 in the MCG data set (Table 1) . To correct for multiple testing, we set the significance threshold at Pp0.0024 (0.05/21) as confirmatory evidence. A total of 10 SNPs reached this significance level in the MCG data set ( Table 1 ). The confirmed loci include four well-known T1D genes: PTPN22 (Po10
). Two other intervals (ERBB3, Po10 À6 and SH2B3, Po10
À7
) have also been reported in multiple studies and can be considered as confirmed T1D loci, although the disease genes have not been identified.
We next assessed associations after stratification with sex, age of onset of diabetes or human leukocyte antigen (HLA) risks. As shown in Table 2 , there was no significant difference between the early-and late-onset patient subsets; however, the early-onset patients provided more association evidence for SIRPG (P ¼ 0.0015) that did not quite reach the significance threshold (P ¼ 0.0008) after correcting for the number of tested loci (n ¼ 21) and number of corrections (n ¼ 3). Association analysis after stratification by sex revealed three SNPs that showed significant heterogeneity between men and women (Table 3) . Although the association with the ITPR3 interval did not meet our significance threshold in the entire data set, the SNP is significantly associated with T1D in women after correction for multiple tests (odds ratio ¼ 0.8 and P ¼ 0.00055), providing confirmatory evidence for the SNP in the Georgia population. Association with C14orf181 in women ( Table 3 ) (P ¼ 0.0016) became stronger but did not reach the significance level. We also performed association analysis after stratification with disease risk based on HLA genotypes. All patients are grouped into two subsets, one with the high-risk DQB1 genotypes (0201/ 0201, 0302/0302 or 0201/0302) and the second subset with low-risk DQB1 genotypes (all others). These analyses revealed marginally significant heterogeneity for the SNPs near PKCQ (P ¼ 0.036) and IFIH1 (P ¼ 0.07) (Supplementary Table 1 ). Stratification by HLA did not provide confirmatory evidence for any additional SNP.
Discussion
This follow-up study evaluated association between T1D and 21 GWA SNPs selected from previous GWAS. All the SNPs showed association in the same direction except one SNP in the gene CTSH rs3825932. The odds ratios in this study are not significantly different from the other studies. Our results suggest that 18 SNPs showed putative evidence for associations in the MCG data set. Together with evidence reported in other populations, these results indicate that these 18 non-HLA genes are associated with T1D in the Georgia Caucasian population. Out of 18, 10 SNPs remained significant after correcting for multiple testing (Po0.0024 level), and 1 additional SNP became significant after correcting for multiple testing and stratification by sex. This study provides additional evidence that the associations identified by GWAS might represent genuine susceptibility genes for T1D. The main finding of the GWAS and subsequent studies is the large number of associated intervals. An intrinsic problem with GWAS is the potentially high false-positive rate because of the large number of markers analyzed in the studies. 21 The loci with evidence in multiple studies are likely to contain susceptibility genes.
The GWAS and subsequent confirmation studies also suggested that all non-HLA genes appear to have very weak contribution to T1D susceptibility. The previously confirmed disease genes such as INS and PTPN22 are among the stronger non-HLA T1D-susceptibility genes. [22] [23] [24] [25] The newly discovered T1D-association intervals generally have weaker contribution. The weak effect of these susceptibility genes poses a serious challenge for the identification of the specific variants implicated in the disease. This task will require extensive sequencing and genotyping of large number of subjects for all genes in the associated loci, as well as functional characterization of the associated genes and variants. Identification of the specific disease genes, and elucidation of the underlying functional mechanism will undoubtedly contribute valuable information for understanding the pathogenesis of T1D. T1D-susceptibility genes, particularly the HLA class II genes, have been widely used in population-based studies for the identification of high-risk individuals. Although HLA genes allow the identification of a population at increased risk for the development of T1D, testing HLA genes alone lacks specificity, sensitivity and positive predictive value. It has been hoped that the identification of the non-HLA genes would increase the predictive value of genetic testing for T1D. It is believed by some investigators that the use of computer-based modeling approaches with GWA data might be able to improve the assessment of disease risk. 26 This might be possible only if significant gene-gene and/or geneenvironment interactions occur. Although such interactions are certainly expected to occur in T1D, there is no available evidence to suggest that they will significantly improve our ability to accurately identify the high-risk subjects with high specificity and sensitivity. One remaining hope to gain predictive value with T1D-susceptibility genes is the possibility that rare variants, with much larger effect on disease, that are difficult to detect by GWAS, will be identified by large-scale sequencing studies.
Materials and methods

Study populations
The study population consists of 1434 Caucasian T1D patients and 1864 healthy controls from Georgia. 27 The samples were selected only if all the four grandparents were having European heritage. All diabetic patients were diagnosed using the criteria of the American Diabetes Association. Most of the cases (893) developed T1D at or before the age of 17 years, and this group of patients will be referred to as early-onset patients. A subset of patients (541) developed diabetes after 17 years of age and these patients were referred to as late-onset diabetes for data analysis purposes. The controls were normal subjects without a family history for T1D and they were ascertained from the same geographic area as the patients. We have included only those subjects who have genetic heritage of European Caucasians based on the family history of the subjects.
SNP genotyping
A total of 40 loci were initially genotyped in a subset of the MCG sample set using the TaqMan assay method. 28 The 21 loci showing consistent results with GWAS were further genotyped in the entire data set and the results were reported here. All assays (primers and probes) used in this study were designed and validated by Applied Biosystems (Foster City, CA, USA). Amplification reactions were performed in a 5 ml final volume in optical 384-well plates. PCR was carried out with the following conditions: 2 min at 50 1C, 10 min at 95 1C followed by 40 cycles of 15 s at 95 1C and 1 min at 60 1C using an ABI9700 Real-Time PCR system (Applied Biosystems). The method was validated by other methods such as restriction-fragment length polymorphism. A subset of samples has been tested twice and only assays with acceptable concordance are included in the manuscript. The call rate was above 96% for all the markers and all the SNPs were in Hardy-Weinberg equilibrium in the controls group.
Statistical analysis for SNP association
Association between each SNP and T1D was assessed using logistic regression to fit an additive model. The analysis was carried out using PLINK software (http:// pngu.mgh.harvard.edu/~purcell/plink//). Heterogeneity is used to assess whether the observed variability between studies, strata and subgroups is greater than that expected to occur by chance. Breslow-Day test was used to test for heterogeneity between different strata. Statistical software stats direct was used to calculate heterogeneity (http://www.statsdirect.com/).
